The effects of cromakalim on the mediator releases from guinea pig lung mast cell activated by specific antigen-antibody reactions.
The inhibitory effect of cromakalim on the mediator release from mast cells caused by antigenantibody reactions was in controversy with the specific antigen used. However, it has recently been observed that cromakalim inhibits the release of mediators from superfused tracheal and parenchymal strips or lung mast cells after passive sensitization with the IgG1 antibody. An attempt, therefore, was made to determine the inhibitory mechanisms of cromakalim on the release of mediators such as histamine and leukotriene released by the activation of enzymes during mast cell activation. Guinea pig lung mast cells were purified through enzyme digestion, rough percoll and continuous percoll density gradients. The purified mast cells were prelabeled with [3H]palmitic acid. PLD activity was assessed more directly by the production of labeled phosphatidylethanol by PLD-mediated transphosphatidylation in the presence of ethanol. In the cells labelled with [3H]myristic acid, [3H] DAG production was measured. The methyltransferase activity was assessed by measuring the incorporation of [3H]methyl moiety into phospholipids in sensitized mast cells labelled with L-[3H] methylmethionine. cAMP level was measured by radioimmunoassay. Cromakalim resulted in a decrease in the amount of histamine and leukotrienes releases by 30% in the ovalumin-induced mast cell. Cromakalim had little effect on phospholipase D activity enhanced by the activated mast cell. Cromakalim inhibited the initial increase of diacylglycerol production during mast cell activations. Cromakalim inhibited the phospholipid methylation increased in the activated mast cell. These results show that cromakalim decreases histamine release by inhibiting the initial increase of 1,2-diacylglycerol during the mast cell activation, which is mediated via the phosphatidylinositide-phospholipase C system rather than the phosphatidylcholine-phospholipase D system. Furthermore, cromakalim reduces phosphatidylcholine production by inhibiting the methyltransferase, which decreases the conversion of phosphatidylcholine into arachidonic acid and inhibits the production of leukotrienes.
Ro
J Y
JY
Department of Pharmacology, Yonsei University College of Medicine, Seoul, Korea.
Yim
Y N
YN
Kim
K H
KH
D000262:Adenylyl Cyclases / Q000378:metabolism; D000818:Animals; D000937:Antigen-Antibody Reactions; D001578:Benzopyrans / Q000494:pharmacology*; D019806:Cromakalim; D004075:Diglycerides / Q000096:biosynthesis; D005260:Female; D006168:Guinea Pigs; D006636:Histamine Release / Q000187:drug effects*; D015289:Leukotrienes / Q000378:metabolism*; D008168:Lung / Q000187:drug effects / Q000378:metabolism; D008407:Mast Cells / Q000187:drug effects* / Q000378:metabolism; D008745:Methylation; D010739:Phospholipase D / Q000378:metabolism; D010743:Phospholipids / Q000378:metabolism; D015221:Potassium Channels / Q000187:drug effects*; D011758:Pyrroles / Q000494:pharmacology*
C011439:1,2-diacylglycerol; D001578:Benzopyrans; D004075:Diglycerides; D015289:Leukotrienes; D010743:Phospholipids; D015221:Potassium Channels; D011758:Pyrroles; D019806:Cromakalim; D010739:Phospholipase D; D000262:Adenylyl Cyclases